Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349721 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
A Phase 2 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT05349721: Clinical Trial Phase 2 study, sponsored by PTC Therapeutics.
NCT05349721 is a Phase 2 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 336 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349721, a Phase 2 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
Primary Outcome
The CAFS is a composite endpoint based on time to earlier occurrence of death and change from baseline in ALSFRS-R score. ALSFRS-R is a rating scale where 12 functions were rated on 5-point scales (from 0 to 4) with a maximum score of 48 (sum of all 12 items), with a higher score indicating better function. Each participant's outcome was compared to every other participant's outcome in a pairwise fashion by time to death and change on ALSFRS-R, assigned a score which was sum of comparisons (+1 \
Interventions
- DRUG Placebo
- DRUG PTC857
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Why NCT05349721 stopped before completion
NCT05349721 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05349721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05349721 about?
NCT05349721 is a clinical study titled "Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS". This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
What is the current status of trial NCT05349721?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2022-05-15. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT05349721?
The interventions under investigation include: Placebo (DRUG), PTC857 (DRUG).
Who is sponsoring clinical trial NCT05349721?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05349721's enrollment target sits among peer trials
336 141st of 2000 higher than 1,859 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI